TipRanksStock Market NewsPTCT NewsPTC Therapeutics (PTCT) Gets a Hold Rating from RBC Capital

PTC Therapeutics (PTCT) Gets a Hold Rating from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on PTC Therapeutics (PTCTResearch Report) on April 6 and set a price target of $42.00. The company’s shares closed last Thursday at $43.00.

According to TipRanks.com, Abrahams is a 1-star analyst with an average return of 0.0% and a 46.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Corbus Pharmaceuticals.

PTC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on PTC Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $165 million and GAAP net loss of $143 million. In comparison, last year the company earned revenue of $119 million and had a GAAP net loss of $74.35 million.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Read More on PTCT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More